Precision Medicine Podcasts

Mindera Health™ Signs Network Provider Agreement with MultiPlan

Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™.

“Our vision is to realize the clinical and economic benefits of precision guided biologic class selection by enabling the broadest access to our testing for psoriasis patients and the providers that are charged with caring for them,” said Mindera CEO Ron Rocca. “We are thrilled to have the opportunity to work with a leader like MultiPlan whose networks touch so many lives and provide provider network solutions to so many employers and payers.”

In the United States, psoriasis affects more than three percent[i] of the population, leading to healthcare costs of more than $110 billion annually[ii]. Specialty drug spending for psoriasis is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year[iii]. Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.

About Mindera Health
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].

About MultiPlan
MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the US healthcare system. Our focus is on identifying medical savings, helping to lower out-of-pocket costs, and reducing or eliminating balance billing for healthcare consumers. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.


i. Menter A, Stroeber B, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4): 1029-1072.


ii. Pilon D, Teeple A, Zhandava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States, J Med Econ. 2019;22(2):196-203. doi:10/180/13696998.2018.1557201.


iii. Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”


iv. Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JD Innovations. 2021;1:100025


v. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5


vi. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

 

Mindera Health™ Welcomes New Vice President of Sales

– Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the addition of John Wegener as the New VP of Sales.

John has deep experience and impressive accomplishments across his career, including most recently 10 years as Senior Vice President Sales and Marketing at Exagen Inc. and 14 years at Prometheus Laboratories as National Director of Managed Markets. At both organizations John was able to take start-up organizations and turn them into commercial sales leaders.

“We are thrilled to welcome John to the Mindera team,” said Ron Rocca, President and CEO. “I have worked closely with John in the past and find that his extensive experience in diagnostic sales and deep understanding of managed markets will be extremely valuable as we continue to innovate and expand. John shares our commitment to excellence, and we are confident that he will help us achieve new heights in patient, physician, and payor satisfaction as well as revenue growth.”

John expressed excitement about the new role: “I am honored to join Mindera Health at such an exciting time in its growth journey. I look forward to working alongside the talented team here to drive meaningful results and provide all our customers with the highest level of service.” As Vice President of Sales, John will oversee all aspects of Mindera Health’s sales operations, including strategic planning, team development, and customer acquisition. His appointment is part of Mindera Health’s continued commitment to strengthening its leadership team and driving sustainable growth.

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. 

About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[i]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annually. [ii]

 

i. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5


ii. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Mindera Health™ Announces Issuance of Additional International Patent Coverage for Dermal Biomarker Patch Platform

Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Japan for the core technology behind the dermal biomarker patch.

Japanese patent number JP7572774 was issued October 16, 2024 and describes devices that can extract dermal biomarkers in situ. The inventors discovered that a covalently modified patch can efficiently capture and extract meaningful quantities of biomarkers from the skin. This patent adds to existing patent protection for the dermal biomarker patch technology in the United States, Europe, Australia, China, Hong Kong, and Korea. This brings the total number of issued or allowed patents related to the Company’s dermal biomarker patch technology to 11.

“We are pleased to have been issued additional patent coverage in Japan for the Dermal Biomarker Patch,” said Tobin Dickerson, Mindera Health’s chief scientific officer and co-founder. “This technology underpins tests such as Mind.Px™, a test designed to optimize psoriasis biologic treatment decisions and reduce trial and error treatment paradigms. As we expand the platform into other indications, we aim to more broadly bring precision medicine to dermatology.”

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[i]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annually.[ii]

  1. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5
  2. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Mindera Health Partners with National Psoriasis Foundation to Advance Precision Medicine in Psoriasis Treatment

Mindera Health and National Psoriasis Foundation partner to improve psoriasis patient outcomes and raise awareness of precision medicine.

 

Vista, CA- November 19, 2024- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis Foundation (NPF), the largest patient advocacy organization dedicated to serving those with psoriasis and psoriatic arthritis.


Mindera Health’s Mind.Px™, the first and only predictive test of its kind, uses advanced gene expression analysis to help dermatologists determine the most effective biologic class for the treatment of individual psoriasis patients. By partnering with the NPF, Mindera Health aims to drive awareness of personalized medicine and accelerate the adoption of this innovative technology to improve patient outcomes nationwide.


“Our partnership with the National Psoriasis Foundation represents a pivotal moment in psoriasis care,” said Ron Rocca CEO of Mindera Health. “Precision medicine is the future. Mindera Health is excited to be the first to bring precision medicine to psoriasis patients. We are aligned with the National Psoriasis Foundation’s goal to improve patient care and look forward to working with the NPF.”


NPF helps more than 4 million people annually with resources, tools, and information that allows for better decisions for the care and management of psoriatic disease. While psoriasis and PsA are complicated diseases with serious consequences, NPF does a remarkable job of simplifying the patient’s journey with programs like the NPF Care Path. Together, Mindera Health and NPF can continue to help patients, and their doctors make more efficient and accurate treatment decisions.


For more information about Mindera Health and Mind.Px™, visit www.MinderaHealth.com. To learn more about the National Psoriasis Foundation, visit www.psoriasis.org.


About Mindera Health
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.


About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[i]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annually. [ii].


About the National Psoriasis Foundation
The National Psoriasis Foundation has served the community of people impacted by psoriatic disease since 1967 with patient support, advocacy, research, and education. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. Learn more at www.psoriasis.org.

 

i. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5


ii. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

 

Mindera Health™ becomes a Medi-Cal™ Credentialled Provider

Provider status with Medi-Cal will allow Mindera Health to provide its proprietary Mind.Px test to predict biologic class response in plaque psoriasis to the over 15 million Medi-Cal Beneficiaries.

San Diego, CA, Aug 19, 2024 (GLOBE NEWSWIRE) — Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling process to become a Medi-Cal provider making its services available to the over 15 million Californians that rely on the state’s Medicaid program for health insurance coverage.

In the United States, psoriasis affects more than three percenti of the population. Moderate-to-severe disease severity accounts for approximately one-third of psoriasis diagnoses.ii This auto-immune condition often leads to absenteeism or major problems at work, depression, and other clinical comorbidities.ii Specialty drug spending for psoriasis is escalating exponentially, and biologics are often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year.iii Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentiv, leading to trial-and-error treatment selection and increased healthcare costs.

Mind.Px is a predictive test that uses a patented dermal biomarker patch allowing for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value.v By leveraging precision medicine and matching the patient to the right drug class before treatment begins, clinical outcomes can be improved while biologic drug expenditures are optimized.

“We are delighted to have the opportunity to serve the 1 in 3 Californian’s insured as Medi-Cal beneficiaries,” says Ron Rocca, CEO of Mindera Health. “We look forward to partnering with the largest single payer in our home state and its affiliated managed care plans to address the rising costs and optimize clinical outcomes associated with biologic therapy in plaque psoriasis.”

About Medi-Cal™

According to the Californian Health Care Foundation, Medi-Cal, California’s Medicaid program, is the state’s health insurance program for Californians with low income, including nearly four in ten children, one in five nonelderly adults, and two million seniors and people with disabilities. In total, over 15 million Californians – one in three – rely on the program for coverage. Medi-Cal pays for essential primary care, specialty, acute, behavioral health and long-term care services.

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About Mind.Px™

Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].

I Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):10291072. doi:10.1016/j.jaad.2018.11.057.

ii Van Voorhees AS, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide, 7th ed. Table 2-3. https://psoriasis.org/the-pocket-guide.

iii Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”

iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

v Bagel J, Wang Y, Montgomery P III, et al. A machine learning-based test for predicting response to psoriasis biologics.SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5

vi Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Contact:
Scot Nelson

Mindera Health

scot.nelson@minderahealth.com

858-810-6070

Mindera Health Announces Appointment of Kamal Adawi as Chief Financial Officer

Mindera Health announces the appointment of Kamal Adawi as Chief Financial Officer, effective August 14th, 2024.

San Diego, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) — Ron Rocca, President and CEO of Mindera Health, said, “We’re very pleased to add Kamal to the executive team. I am thrilled to work with Kamal again as he will add the strategic focus and long-term financial vision needed to fuel our innovation and growth. The Mindera Health platform provides us with an incredible opportunity to grow our plaque psoriasis product, and to continue to innovate and create additional personalized medicine solutions in dermatology and beyond. I look forward to working with Kamal as we invest responsibly to support our current offerings and the next wave of growth.”

Kamal has held numerous senior financial positions during his over 20-year career with both private and public organizations. He was instrumental Exagen’s Initial Public Offering in September of 2019. He received his Bachelor of Arts in Finance from Michigan State University, his Master of Business Administration from Oakland University and his Master of Science in Finance from San Diego State University.

About Mind.Px™

Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification.

I Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):10291072. doi:10.1016/j.jaad.2018.11.057.

ii Van Voorhees AS, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide, 7th ed. Table 2-3. https://psoriasis.org/the-pocket-guide.

ii[1] Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”

[1]v Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

V Mindera Health. Data on file.

Find out more at www.minderahealth.com, and connect with Mindera Health on Facebook, Twitter, LinkedIn, and YouTube.

Mindera Health Secures $14 Million to Advance Commercialization of First and Only Psoriasis Precision Medicine Test

San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) — Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in anticipation of a Series B financing in 2025. Proceeds will support the continued commercialization of Mindera’s lead product, Mind.Px™.

“This capital raise will fuel the organization’s continued commercial growth. The use of Mind.Px™ can effectively eliminate today’s trial-and-error approach to psoriasis treatment by providing physicians, patients, and payors with a powerful tool to guide the individual patient to an efficacious drug class based on their biomarker profile. Mind.Px™ is helping precision medicine become the standard of care in dermatology,” said Ron Rocca, CEO of Mindera Health.

“We are excited to continue our partnership with Mindera and remain committed to improving patient outcomes in psoriasis with Mind.Px™,” said Joe Cook, III, Managing Director at Mountain Group Partners and Chairman of Mindera Health. “We believe the company’s novel, patented approach to precision therapy selection has the potential to address a myriad of unmet needs across the dermatological treatment landscape.”

About Mind.Px™

Mind.Px™ is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px™ materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification.

About Mountain Group Partners

Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies, predominantly in the life science and disruptive technology sectors. The firm brings over 70 years of combined operational experience and has made investments in more than 75 companies. Mountain Group takes a hands-on approach to investing based on its deep operational experience and currently has over $300 million in assets under management. For more information on Mountain Group Partners, visit www.mtngp.com

Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine

Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies

Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with Liviniti™, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to improve clinical outcomes while reducing biologic drug costs for self-funded employers. 

In the United States, psoriasis affects more than three percent [i] of the population. Moderate-to-severe disease severity accounts for approximately one-third of psoriasis diagnoses.[ii]This auto-immune condition often leads to absenteeism or major problems at work, depression, and other clinical comorbidities.[ii] Specialty drug spending for psoriasis is escalating exponentially, and biologics are often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year. [iii] Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.

Mind.Px is a predictive test that uses a patented dermal biomarker patch allowing for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive value.[v] By leveraging precision medicine and matching the patient to the right drug class before treatment begins, clinical outcomes are improved while biologic drug expenditures are optimized.

“We are delighted to partner with a Pharmacy Benefit Manager like Liviniti to introduce precision medicine to psoriasis patients,” says Ron Rocca, CEO of Mindera Health. “We share the core value of introducing innovation to significant markets to decrease drug costs while improving patient outcomes.”

LeAnn C. Boyd, Liviniti CEO adds, “Inflammatory conditions are a major cost trend driver in the specialty pharmacy space. Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members.”

About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Liviniti™
Liviniti is a pioneer in pharmacy benefit innovation. Built by pharmacists, the company offers pass-through pricing within a fully transparent business model that delivers meaningful savings to clients and optimal health outcomes to members. Founded in 2011 as Southern Scripts and rebranded to Liviniti in 2023, the new name reinforces the power of medication to change lives through infinite possibilities. With an approach that delivers savings, clinical value, exceptional service and management of high-cost medications, Liviniti provides pharmacy benefit services to regional and national employers across the US. For more information, visit Liviniti.com.

About Mindera Health
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. 

i Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):10291072. doi:10.1016/j.jaad.2018.11.057.

ii Van Voorhees AS, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide, 7th ed. Table 2-3. https://psoriasis.org/the-pocket-guide.

ii Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”

iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

V Mindera Health. Data on file.

Mindera Health ™ Announces Commercial Relocation

San Diego, CA – November 27th, 2023 – Mindera Health™, a leading provider of precision medicine solutions for psoriasis, today announced that it will be relocating its commercial activities to a new office building at 1221 Liberty Way, Vista, CA 92081 on December 1st, 2023. The new facility is over 19,000 square feet and features a state-of-the-art molecular laboratory.

“As we continue to accelerate our commercial activities, it is necessary to have a state-of-the-art facility that will enable us to expand,” said Ron Rocca, President, and CEO of Mindera Health. “The new building gives us some great collaborative spaces that have already had a positive impact on our projects.”

The new Mindera Health office is designed to foster innovation and collaboration, with open workspaces, meeting rooms, and a dedicated break area. The laboratory is equipped with the latest technology and equipment, allowing Mindera Health to continue to develop and commercialize its innovative precision medicine solutions for psoriasis.

Mindera Health will continue to operate its Kearny Mesa laboratory as licenses and accreditations are transferred to the new location.

“We are excited to move into our new office and laboratory,” said Toby Dickerson, Chief Scientific Officer and Co-Founder. “This is a significant milestone for Mindera Health, and it is a testament to our growth and commitment to providing patients with the best possible care.”

About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

 

Ron Rocca

Mindera Health

(858) 810-6070

ron.rocca@minderahealth.com

 

 

Contact

  • General Contact:
    858-810-6070
    Address:
    1221 Liberty Way, Vista, CA 92081
Twitter Linkedin Youtube

Hours

  • Monday-Friday 7:00AM – 5:00PM PST

Mindera Health

© Copyright 2025, Mindera Health I ISO 13485:2016 certified Privacy Policy I Terms of Use